Axsome Therapeutics (AXSM) has quickly moved onto investors' radar after the FDA accepted a priority review for AXS-05 in Alzheimer’s agitation and signaled support for an NDA filing for narcolepsy ...
Zacks Investment Research on MSN
AXSM up on FDA priority review to AXS-05 sNDA in Alzheimer's agitation
Shares of Axsome Therapeutics AXSM were up 22.8% on Dec. 31, after it announced that the FDA had accepted the supplemental ...
The US Food and Drug Administration (FDA) has accepted for filing Axsome Therapeutics’ supplemental New Drug Application (NDA ...
FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026NEW YORK, (GLOBE NEWSWIRE) -- ...
New Drug Application (NDA) submission on track for January 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome ...
Axsome just received priority review designation for its most important drug. Auvelity is an oral medication already approved ...
Zacks Investment Research on MSN
AXS stock moves above 50 & 200-day SMA: Buy, sell or stay invested?
Shares of Axis Capital Holdings AXS have gained momentum. The stock is trading above its 50 and 200-day simple moving average ...
FDA grants priority review to Axsome's AXS-05 for treating agitation in Alzheimer's disease with a PDUFA date of April 30, 2026.
AXS, the global advanced ticketing and live event technology company, has announced two key leadership appointments as part of its continued technology transformation and global growth. Nikhil Bobde ...
AXS-05 demonstrated a statistically significant mean reduction from baseline in the MADRS total score of 7.3 points for AXS-05 compared to 4.9 points for placebo at Week 1 (p=0.007), with statistical ...
New hires underscore ticketing company's global growth strategy and focus on next-gen fan experiences By Dave Brooks AXS is bolstering its executive team with two major technology appointments. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback